EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer

Gengwei Huo iD, Wenjie Liu iD, Peng Chen iD

Journal of Gynecologic Oncology · 2024 · 35 (5)

DOI: 10.3802/jgo.2024.35.e58 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Gengwei Huo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Cost-Benefit Analysis, Markov Chains, Quality-Adjusted Life Years. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China anti-cancer association HER2 target Chinese research fund, Tianjin education commission for higher education, Tianjin key medical discipline (specialty) construction project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the cost-effectiveness of tisotumab vedotin to treat recurrent or metastatic cervical cancer in second- or third-line from the U.S. payer perspective. METHODS: A Markov model with three-state was employed to simulate recurrent or metastatic cervical cancer patients who were administered either tisotumab vedotin or investigator's choice of chemotherapy based on the phase III, open-labeled innovaTV 301 randomized clinical trial. The data on cost and health preferences were collected from the literature. RESULTS: Tisotumab vedotin generated an additional 0.25 quality-adjusted life-years (QALYs) compared to chemotherapy, but at an additional cost of $206,779. This results in incremental cost-effectiveness ratios of $839,107.88 per QALY. The results of the univariate sensitivity analysis indicated that cost of tisotumab vedotin, utility of progressive disease and progression-free survival had the greatest impacts on the outcomes. Probability sensitivity analysis showed that tisotumab vedotin had a 0% chance of being considered cost-effective. CONCLUSION: Tisotumab vedotin was unlikely cost-effective compared to chemotherapy for recurrent or metastatic cervical cancer patients at a willingness-to-pay threshold of $150,000/QALY from the perspective of a U.S. payer. Lowering the prices of tisotumab vedotin could potentially enhance its cost-effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsCost-Benefit AnalysisMarkov ChainsQuality-Adjusted Life YearsNeoplasm Recurrence, LocalHumansFemaleProgression-Free SurvivalAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalUnited States

Stichwörter der Autor:innen

Cervical CancerCost-Effectiveness AnalysisQuality-Adjusted Life YearsTisotumab Vedotin

Substanzen

Antibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • National Clinical Research Center for Cancer, Tianjin, China.
  • Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.
  • Tianjin's Clinical Research Center for Cancer, Tianjin, China.
  • Tianjin's Clinical Research Center for Cancer, Tianjin, China. chenpengdoc@sina.com.

ORCID-Profile: Gengwei Huo, Wenjie Liu, Peng Chen

Förderung

  • China anti-cancer association HER2 target Chinese research fund
  • Tianjin education commission for higher education
  • Tianjin key medical discipline (specialty) construction project

Zitieren

APA

Huo, G., Liu, W., & Chen, P. (2024). Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer. Journal of Gynecologic Oncology, 35(5). https://doi.org/10.3802/jgo.2024.35.e58

Vancouver

Huo G, Liu W, Chen P. Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer. Journal of Gynecologic Oncology. 2024;35(5). doi:10.3802/jgo.2024.35.e58

BibTeX
@article{Huo2024,
  author = {Huo, Gengwei and Liu, Wenjie and Chen, Peng},
  title = {Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  volume = {35},
  number = {5},
  doi = {10.3802/jgo.2024.35.e58}
}
Kostenlos starten →